Secukinumab (AIN-457) for the treatment of Psoriasis

被引：10

作者：

Jaleel, Tarannum ^{[1
]}

Elmets, Craig ^{[1
]}

Weinkle, Allison ^{[3
]}

Kassira, Sama ^{[2
]}

Elewski, Boni ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Dept Dermatol, EFH 414,1530 3rd Ave S, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA

[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 02期

关键词：

pharmacology; IL-17; Th; 17; AIN-457; psoriasis; secukinumab; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; MULTIPLE-SCLEROSIS; TH17; CELLS; INFLIXIMAB INDUCTION;

D O I：

10.1586/17512433.2016.1129894

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.

引用

页码：187 / 202

页数：16

共 116 条

[51] Role of Interleukin 17 in Inflammation, Atherosclerosis, and Vascular Function in Apolipoprotein E-Deficient Mice [J].

Madhur, Meena S. ;

Funt, Samuel A. ;

Li, Li ;

Vinh, Antony ;

Chen, Wei ;

Lob, Heinrich E. ;

Iwakura, Yoichiro ;

Blinder, Yelena ;

Rahman, Ayaz ;

Quyyumi, Arshed A. ;

Harrison, David G. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (07) :1565-U188

[52] Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis [J].

Marder, Wendy ;

Khalatbari, Shokoufeh ;

Myles, James D. ;

Hench, Rita ;

Yalavarthi, Srilakshmi ;

Lustig, Susan ;

Brook, Robert ;

Kaplan, Mariana J. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (09) :1550-1555

[53] Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis [J].

Mariette, Xavier ;

Matucci-Cerinic, Marco ;

Pavelka, Karel ;

Taylor, Peter ;

van Vollenhoven, Ronald ;

Heatley, Rebecca ;

Walsh, Claire ;

Lawson, Richard ;

Reynolds, Alan ;

Emery, Paul .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (11) :1895-1904

[54] Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

McInnes, Iain B. ;

Mease, Philip J. ;

Kirkham, Bruce ;

Kavanaugh, Arthur ;

Ritchlin, Christopher T. ;

Rahman, Proton ;

Van der Heijde, Desiree ;

Landewe, Robert ;

Conaghan, Philip G. ;

Gottlieb, Alice B. ;

Richards, Hanno ;

Pricop, Luminita ;

Ligozio, Gregory ;

Patekar, Manmath ;

Mpofu, Shephard .

LANCET, 2015, 386 (9999) :1137-1146

[55] Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial [J].

McInnes, Iain B. ;

Sieper, Joachim ;

Braun, Juergen ;

Emery, Paul ;

van der Heijde, Desiree ;

Isaacs, John D. ;

Dahmen, Georg ;

Wollenhaupt, Juergen ;

Schulze-Koops, Hendrik ;

Kogan, Joseph ;

Ma, Shenglin ;

Schumacher, Martin M. ;

Bertolino, Arthur P. ;

Hueber, Wolfgang ;

Tak, Paul P. .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (02) :349-356

[56]

Mease P, 2014, ARTHRITIS RHEUMATOL, V66, pS423

[57] Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis [J].

Mease, Philip J. ;

McInnes, Iain B. ;

Kirkham, Bruce ;

Kavanaugh, Arthur ;

Rahman, Proton ;

van der Heijde, Desiree ;

Landewe, Robert ;

Nash, Peter ;

Pricop, Luminita ;

Yuan, Jiacheng ;

Richards, Hanno B. ;

Mpofu, Shephard .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (14) :1329-1339

[58] Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial [J].

Mease, PJ ;

Gladman, DD ;

Ritchlin, CT ;

Ruderman, EM ;

Steinfeld, SD ;

Choy, EHS ;

Sharp, JT ;

Ory, PA ;

Perdok, RJ ;

Weinberg, MA .

ARTHRITIS AND RHEUMATISM, 2005, 52 (10) :3279-3289

[59] Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial [J].

Menter, Alan ;

Tyring, Stephen K. ;

Gordon, Kenneth ;

Kimball, Alexa B. ;

Leonardi, Craig L. ;

Langley, Richard G. ;

Strober, Bruce E. ;

Kaul, Martin ;

Gu, Yihua ;

Okun, Martin ;

Papp, Kim .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (01) :106-115

[60] A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis [J].

Menter, Alan ;

Feldman, Steven R. ;

Weinstein, Gerald D. ;

Papp, Kim ;

Evans, Robert ;

Guzzo, Cynthia ;

Li, Shu ;

Dooley, Lisa T. ;

Arnold, Cynthia ;

Gottlieb, Alice B. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (01) :31-44

← 1 2 3 4 5 6 7 8 9 10 →